Skip to main content

Table 4 Cox proportional hazard analysis for overall survival

From: Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis

 

Univariate

Multivariate

Set A

Set B

HR (95%CI)

p-value

HR (95%CI)

P-value

HR (95%CI)

p-value

Age, ≥ 65

1.16 (0.67–2.00)

0.606

    

Sex, men

0.80 (0.25–2.57)

0.704

    

Smoking status, ever-smokers

0.25 (0.09–0.71)

0.009

0.30 (0.10–0.90)

0.032

0.28 (0.09–0.84)

0.023

ECOG-PS, 0–1

0.34 (0.16–0.71)

0.004

0.38 (0.18–0.82)

0.014

0.39 (0.19–0.84)

0.015

Stage, III

0.73 (0.41–1.32)

0.298

    

Pathology, uNSCLC (vs. cNSCLC)

1.27 (0.75–2.16)

0.381

1.29 (0.75–2.22)

0.352

1.25 (0.72–2.16)

0.434

PD-L1,

      

≥ 50%

0.61 (0.34–1.10)

0.102

0.58 (0.32–1.06)

0.076

  

≥ 1%

0.88 (0.51–1.51)

0.638

  

0.80 (0.45–1.42)

0.451

Line of treatment, 1st-line

1.10 (0.49–2.46)

0.812

    
  1. CI, confidence interval; cNSCLC, common non-small cell lung cancer; ECOG-PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PD-L1, programmed death ligand-1; uNSCLC, uncommon non-small cell lung cancer
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us